Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for prostate cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Corrigendum to "Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of ProstateCancer" [Eur Urol 2010;58:803-15]. 28065364 2019 11 20 1873-7560 59 3 2011 Mar European urology Eur. Urol. Corrigendum to "Systematic Review of the Efficacy and Safety of High-Intensity Focussed Ultrasound for the Primary and Salvage Treatment of ProstateCancer" [Eur Urol 2010;58:803-15]. 476 S0302-2838(10)01144-9 10.1016/j.eururo.2010.11.042
First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostatecancer: a systematic review of ten randomised clinical trials. The aim of this study is to systematically evaluate all available treatment options in chemotherapy-naive patients with metastatic castration-resistant prostatecancer (mCRPC). We systematically searched PubMed, EMBASE, and the Cochrane libraries up to 1 March 2016 for peer-reviewed publications on randomised clinical trials
Rotterdam ProstateCancer Risk Calculator: Development and Usability Testing of the Mobile Phone App The use of prostatecancer screening tools that take into account relevant prebiopsy information (ie, risk calculators) is recommended as a way of determining the risk of cancer and the subsequent need for a prostate biopsy. This has the potential to limit prostatecancer overdiagnosis and subsequent overtreatment. mHealth apps are gaining traction in urological practice and are used by both (...) practitioners and patients for a variety of purposes.The impetus of the study was to design, develop, and assess a smartphone app for prostatecancer screening, based on the Rotterdam ProstateCancer Risk Calculator (RPCRC).The results of the Rotterdam arm of the European Randomized Study of Screening for ProstateCancer (ERSPC) study were used to elaborate several algorithms that allowed the risk of prostatecancer to be estimated. A step-by-step workflow was established to ensure that depending
Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant ProstateCancer: A Meta-Analysis. New treatments, such as sipuleucel-T and androgen receptor- (AR-) directed therapies (enzalutamide (Enz) and abiraterone acetate (AA)), have emerged and been approved for the management of castration-resistant prostatecancer (CRPC). There are still debates over their efficacy and clinical benefits. This meta-analysis aimed to investigate the efficacy and safety of sipuleucel-T and AR (...) with CRPC and was not associated with increased risk of adverse event of grade ≥3 (p > 0.05). However, treatment with sipuleucel-T did not improve time-to-progression and reduction of prostate-specific antigen (PSA) level ≥50% was not significantly different from that with placebo. AR-directed therapies significantly improved overall survival in patients with CRPC and improved time-to-progression and reduction of PSA level ≥50%. AR-directed therapies did not increase risk of adverse event of grade ≥3 (p
What Are the Links of ProstateCancer with Physical Activity and Nutrition? : A Systematic Review Article. Prostatecancer (PCa) is the second most common malignancy in men worldwide. The purpose of this study was to provide a brief synthesis the current knowledge for the effects of physical activity (PA) and nutrition on PCa risk.A systematic review of English languages reviews, meta-analysis, and original articles published from 2009 to 2015 extracted from the following websites: MEDLINE, Web (...) and/or fruit intake with PCa risk was reported in eight of 13 papers. The effect of meat/fat intake on PCa was estimated in four articles finding increased risk. There was heterogeneity between studies, and findings are inconsistent.Physical activity does not significantly reduce the risk of PCa; however, vigorous exercise may reduce the risk of aggressive tumor. Besides, there is a lack of definitive evidence supporting the preventive role of diet against PCa. Due to many other benefits of regular
Impact of Prostatic-specific Antigen Threshold and Screening Interval in ProstateCancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for ProstateCancer Centres. The European Randomised Study of Screening for ProstateCancer trial has shown a 21% reduction in prostatecancer (PC) mortality with prostate-specific antigen (PSA)-based screening. Sweden used a 2-yr screening interval and showed a larger mortality reduction than Finland with a 4-yr (...) between the Finnish and Swedish centres and estimated the impact of different screening protocols.If the Swedish screening protocol had been followed in Finland, 122 additional PC cases would have been diagnosed at screening, 84% of which would have been low-risk cancers, and four leading to PC death. In contrast, if a lower PSA threshold had been applied in Finland, at least 127 additional PC would have been found, with 19 PC deaths.The small number of deaths among cases that would have been
you like to save your information to view later? Create an account and sign in to keep your Decision box results and view them later. You can also: Continue without an account and print your profile when the process is completed ProstateCancer Screening Men between the ages of 55 and 69 with at least a 10-year life expectancy. Screening is appropriate for people who do not carry a disease that affects their life expectancy. The prostate-specific antigen (PSA) blood test is used to screen men (...) ProstateCancer Screening Boîte à décision | Box details Back to the Decision boxes × My account Creating an account and signing in will allow you to keep your Decision box results and view them later. I do not have an account Provide some personal information and create a user account allowing to save your Decision box results and view them later. You can also: I already have an account Please enter your email address and password to access your profile and consult your decision boxes. Email
of the guideline. This guideline updates a previous version: Rodrigues G, Yao X, Loblaw A, Brundage M, Chin J, Genitourinary CancerDisease Site Group. Low-dose rate brachytherapy for patients with low- or intermediate-risk prostatecancer. Toronto (ON): Cancer Care Ontario (CCO); 2012 Oct 31. 55 p. (Evidence-based series; no. 3-10). [165 references] This guideline meets NGC's 2013 (revised) inclusion criteria. UMLS Concepts ICD9CM (185), (60.5) MSH , , , , , , , , MTH , , , , , , , , PDQ , , , , SNOMEDCT_US (...) brachytherapy; no recommendation can be made for or against using 131 Cs or HDR monotherapy. Patients should be encouraged to participate in clinical trials to test novel or targeted approaches to this disease. None provided Prostatecancer Treatment Nuclear Medicine Oncology Radiation Oncology Surgery Urology Physicians To provide oncologists, other health care practitioners, patients, and caregivers with recommendations regarding the use of brachytherapy for patients with prostatecancer that includes
; Evidence Level: Grade B ) Effective shared decision making in prostatecancer care requires clinicians to inform patients about immediate and long-term morbidity or side effects of proposed treatment or care options. ( Clinical Principle ) Clinicians should inform patients about suitable clinical trials and encourage patients to consider participation in such trials based on eligibility and access. ( Expert Opinion ) Care Options by Cancer Severity/Risk Group Very Low-/Low-Risk Disease Clinicians (...) . ( Expert Opinion ) Intermediate-Risk Disease Clinicians should consider staging unfavorable intermediate-risk localized prostatecancer patients with cross sectional imaging (CT or magnetic resonance imaging [MRI]) and bone scan. ( Expert Opinion ) Clinicians should recommend radical prostatectomy or radiotherapy plus ADT as standard treatment options for patients with intermediate-risk localized prostatecancer. ( Strong Recommendation; Evidence Level: Grade A ) Clinicians should inform patients